63rd European Renal Association Congress (ERA 2026)

Updated ALIGN data boost atrasentan potential in IgAN

Results from the final analysis of the phase III ALIGN trial continue to support the efficacy and safety of atrasentan for the treatment of IgA nephropathy (IgAN).